Pang Xue-Lian, Li Qiao-Xin, Ma Zhi-Ping, Shi Yi, Ma Yu-Qing, Li Xin-Xia, Cui Wen-Li, Zhang Wei
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
Onco Targets Ther. 2017 May 19;10:2645-2654. doi: 10.2147/OTT.S133203. eCollection 2017.
The gene mutation is involved in several types of tumors. However, the potential role of the mutation in human primary and paired metastatic colorectal cancer (CRC) among different nationalities is poorly understood. In the present study, we assessed the relationship between mutation status and overall survival (OS) and disease-free survival (DFS) in 230 patients with primary and paired metastatic CRC. The mutation rate in primary CRC tissue was 43.0% (99/230), which was higher than in paired metastatic CRC, which was 31.9% (23/72; <0.001). Clinicopathologically, the gene mutation rate was higher in tumors that had infiltrated more deeply (T3, T4) and in lymph node (LN) metastases (N1/N2) (=0.029 and =0.010, respectively). The gene status did not differ between the Han and Uyghur nationalities in both primary and metastatic CRC. In 72 paired cases, the mutation rate in primary CRC was significantly higher than in metastatic CRC (<0.001) and in metastatic CRC that had infiltrated more deeply (T3, T4) (=0.034). In the metastatic cases, the gene mutation rate was higher in patients aged over 65 years (=0.035). Specifically, mutation was correlated with a poorer OS and DFS (=0.004 and =0.029, respectively). In our study, 35 patients with wild-type who received cetuximab targeted therapy had a better DFS than patients with mutant (=0.029). The results of the current study demonstrate that the status is significantly associated with infiltrating LN metastases and the TNM stage in primary CRC. In addition, the results show that the mutation is significantly more common in primary tumors than in paired metastatic CRC, and the mutation is correlated with a shorter OS and DFS, as patients with wild-type who received cetuximab experienced a longer DFS.
该基因突变与多种类型的肿瘤有关。然而，该突变在不同民族的人类原发性和配对转移性结直肠癌（CRC）中的潜在作用却知之甚少。在本研究中，我们评估了230例原发性和配对转移性CRC患者的基因突变状态与总生存期（OS）和无病生存期（DFS）之间的关系。原发性CRC组织中的突变率为43.0%（99/230），高于配对转移性CRC中的突变率，后者为31.9%（23/72；<0.001）。在临床病理方面，浸润更深（T3、T4）的肿瘤和淋巴结（LN）转移（N1/N2）中的基因突变率更高（分别为=0.029和=0.010）。在原发性和转移性CRC中，汉族和维吾尔族之间的基因状态没有差异。在72对配对病例中，原发性CRC中的突变率显著高于转移性CRC（<0.001）以及浸润更深（T3、T4）的转移性CRC（=0.034）。在转移性病例中，65岁以上患者的基因突变率更高（=0.035）。具体而言，突变与较差的OS和DFS相关（分别为=0.004和=0.029）。在我们的研究中，35例接受西妥昔单抗靶向治疗的野生型患者的DFS优于突变患者（=0.029）。本研究结果表明，该基因状态与原发性CRC中的LN转移浸润和TNM分期显著相关。此外，结果显示该突变在原发性肿瘤中比在配对转移性CRC中明显更常见，并且该突变与较短的OS和DFS相关，因为接受西妥昔单抗治疗的野生型患者的DFS更长。
